Abstract: Poster Presentations |

Quality of Life (QOL) After Lung Reduction: A Randomized Trial FREE TO VIEW

John D. Miller, MD, FCCP; Anne Moore-Cox, CRA; Richard Malthaner, MD, FCCP; Lawrence Tan, MD FCCP; Jeremy Road, MD; The Canadian Lung Volume Reduction Surgery (CLVRS) Trial Group, Canada
Author and Funding Information

SJH, Mc Master University, Hamilton, ON, Canada


Chest. 2003;124(4_MeetingAbstracts):167S. doi:10.1378/chest.124.4_MeetingAbstracts.167S-a
Text Size: A A A
Published online


PURPOSE:  There is no cure for emphysema. Palliation of symptoms is the focus of medical management. In 1995, lung volume reduction surgery (LVRS) was reintroduced as a surgical treatment for symptomatic patients with emphysema and marked lung hyperinflation. Although improved QOL is the primary objective of treatment, few surgical reports utilize specific QOL measures. We present early results from the CLVR Trial with a focus on several QOL outcomes at 3 and 6 months.

METHODS:  Risk (surgical mortality and hospital length of stay) and QOL assessment (Chronic respiratory questionnaire (CRDQ), short form 36 (SF-36), SF-36 Utility and quality adjusted life days(QALDs)) are the outcomes presented from the CLVR trial comparing LVR surgery with rehabilitation and best medical therapy.

RESULTS:  In the CLVR, 58 patients were randomized (30 surgical, 28 medical). There were no 30-days postoperative deaths. The 6-month mortality was 3.6% in the surgical arm and 5% in the medical arm. Median length of hospital stay was 22 days. Patients experienced clinically important and statistically significant improvements in each domain of the CRDQ at 3 and 6 months. Domains of physical functioning in SF-36 were remarkably improved: Physical functioning improved by 25.9 (95%CI 14, 37.5; p<0.001). SF-36 Utility also demonstrated an improvement at 3 months 0.07, (p=0.08) and 0.10 (p=0.13) at 6 months. A gain of 16 QALDs was achieved by 6 months.CONCLUSIONS: LVR surgery requires a lengthy and often difficult hospitalization. Clinically important and statistically significant improvements in QOL are observed at three and six months following LVR.

CLINICAL IMPLICATIONS:  LVRS, with disclosure of surgical risks, should be offered to all suitable patients with moderate to severe emphysema who seek palliation of their symptoms. We await longer term results with interest.

DISCLOSURE:  J.D. Miller, The Canadian Institute of Health Research, grant monies.

Wednesday, October 29, 2003

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543